610
Participants
Start Date
March 11, 2025
Primary Completion Date
June 30, 2030
Study Completion Date
June 30, 2031
Venetoclax
All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. For all ETP/near-ETP T-ALL patients, venetoclax will replace daunorubicin in induction therapy. CAT will replace CAT+ during early intensification. Venetoclax will replace daunorubicin in interim therapy 2 and 4. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
Dasatinib
All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD \<0.01% on day 46, CAT will replace CAT+ during early intensification, and patients will be continuously subjected to dasatinib combined with chemotherapy during early intensification, interim tharapy, reinduction therapy and maintenance therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
homoharringtonine
All T-ALL patients will receive 8 mg/m2/day dexamethasone in induction therapy. All non-ETP T-ALL patients will receive dasatinib after initial window phase in induction therapy. For non-ETP T-ALL patients with MRD ≥0.01% on day 46，CAT+ will be replaced with randomized doses of homoharringtonine (HHT) during early intensification, and HHT will be administrated during reinduction therapy. In maintenance therapy 2, the CTX+Ara-C treatment cycles are reduced to 5, in order to minimize the impact of alkylating agents on fertility.
NOT_YET_RECRUITING
Anhui Medical University Second Affiliated Hospital, Hefei
NOT_YET_RECRUITING
Anhui Provincial Children's Hospital, Hefei
NOT_YET_RECRUITING
Chongqing Medical University Affiliated Children's Hospital, Chongqing
NOT_YET_RECRUITING
Fujian Medical University Union Hospital, Fuzhou
NOT_YET_RECRUITING
Guangzhou Women and Children's Medical Center, Guangzhou
NOT_YET_RECRUITING
Nanfang Hospital, Southern Medical University, Guangzhou
NOT_YET_RECRUITING
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
NOT_YET_RECRUITING
The Affiliated Hospital of Guizhou Medical University, Guiyang
NOT_YET_RECRUITING
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Wuhan Children's Hospital, Wuhan
NOT_YET_RECRUITING
Hunan Children's Hospital, Changsha
NOT_YET_RECRUITING
The Third Xiangya Hospital of the Central South University, Changsha
NOT_YET_RECRUITING
Xiangya Hospital Central South University, Changsha
NOT_YET_RECRUITING
Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjin
NOT_YET_RECRUITING
Children's Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Jiangxi Provincial Children's Hospital, Nanchang
NOT_YET_RECRUITING
Qilu Hospital of Shandong University, Jinan
NOT_YET_RECRUITING
Affiliated Hospital of Qingdao University, Qingdao
NOT_YET_RECRUITING
Children's Hospital of Fudan University, Shanghai
NOT_YET_RECRUITING
Shanghai Children's Hospital, Shanghai
NOT_YET_RECRUITING
Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Xi'an Northwest Women and Children Hospital, Xi’an
NOT_YET_RECRUITING
Shenzhen Children's Hospital, Shenzhen
NOT_YET_RECRUITING
West China Second University Hospital, Chengdu
RECRUITING
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin
NOT_YET_RECRUITING
Hong Kong Children's Hospital, Hong Kong
Institute of Hematology & Blood Diseases Hospital, China
OTHER